These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12162703)

  • 41. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 44. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.
    Frazier KS
    Toxicol Pathol; 2015 Jan; 43(1):78-89. PubMed ID: 25385330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
    Vallières L
    IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
    Branch AD
    Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RAF antisense oligonucleotide as a tumor radiosensitizer.
    Kasid U; Dritschilo A
    Oncogene; 2003 Sep; 22(37):5876-84. PubMed ID: 12947394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genasense (Genta Inc).
    Banerjee D
    Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
    Burnett JR
    Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
    Thomas CE; Will Y
    Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Use of the antisense oligonucleotide technique in neuropsychopharmacology research].
    Yamada M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):129-38. PubMed ID: 8905802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antisense oligonucleotides in cancer.
    Castanotto D; Stein CA
    Curr Opin Oncol; 2014 Nov; 26(6):584-9. PubMed ID: 25188471
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.
    Engelhardt JA; Fant P; Guionaud S; Henry SP; Leach MW; Louden C; Scicchitano MS; Weaver JL; Zabka TS; Frazier KS;
    Toxicol Pathol; 2015 Oct; 43(7):935-44. PubMed ID: 25717082
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EuroTIDES 2005--Sixth Annual IBC Conference. Oligonucleotide, RNAi and peptides for the drug development and manufacturing industry.
    Corey DR
    IDrugs; 2006 Feb; 9(2):105-6. PubMed ID: 16523398
    [No Abstract]   [Full Text] [Related]  

  • 56. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oligonucleotide therapy.
    Crooke ST
    Curr Opin Biotechnol; 1992 Dec; 3(6):656-61. PubMed ID: 1369122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
    Crooke RM; Graham MJ
    Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antisense oligonucleotides for target validation in the CNS.
    Ho SP; Hartig PR
    Curr Opin Mol Ther; 1999 Jun; 1(3):336-43. PubMed ID: 11713799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.